- |||||||||| gavocabtagene autoleucel (TC-210) / Adaptimmune
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker, Metastases: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov) - Mar 6, 2024 P1/2, N=36, Active, not recruiting, Recruiting --> Active, not recruiting | N=175 --> 36 | Trial completion date: Apr 2026 --> Nov 2028 | Trial primary completion date: Jul 2024 --> Nov 2028
- |||||||||| gavocabtagene autoleucel (TC-210) / Adaptimmune, TC-510 / Adaptimmune
Journal, PD(L)-1 Biomarker, IO biomarker: Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. (Pubmed Central) - Dec 11, 2023 These data demonstrate that integration of a PD1-CD28 CSR into TRuC-T cells improves effector function, resistance to exhaustion, and prolongs persistence. Based on these findings, TC-510 is currently being evaluated in patients with MSLN-expressing solid tumors.
- |||||||||| gavocabtagene autoleucel (TC-210) / TCR2 Therap
The Functional Activity of Gavo-cel TRuC-T Cells is not Impaired by Soluble Mesothelin (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_556; P1/2 Furthermore, gavo-cel demonstrates potent efficacy in vivo in a tumor model characterized by circulating sMSLN. Conclusions Our data indicate that both gavo-cel and allogeneic MSLN-targeting TRuC-T cells are not susceptible to functional suppression by sMRPs, even at supraphysiological levels that far exceed those found in cancer patients.
- |||||||||| gavocabtagene autoleucel (TC-210) / Adaptimmune
Enrollment change, Trial completion date, Trial primary completion date, IO biomarker, Metastases: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov) - May 24, 2022 P1/2, N=175, Recruiting, Conclusions Our data indicate that both gavo-cel and allogeneic MSLN-targeting TRuC-T cells are not susceptible to functional suppression by sMRPs, even at supraphysiological levels that far exceed those found in cancer patients. N=70 --> 175 | Trial completion date: Jan 2023 --> Apr 2026 | Trial primary completion date: Dec 2021 --> Jul 2024
- |||||||||| gavocabtagene autoleucel (TC-210) / TCR2 Therap
Engineering off-the-shelf anti mesothelin t-cell receptor fusion construct (TRuC™) t-cells (Section 36) - Mar 9, 2022 - Abstract #AACR2022AACR_2746; To reduce host rejection and further boost the persistence of the allogeneic TRuC-T cells, we eliminated MHC class I surface expression by B2M gene knockout and over-expressed membrane-bound IL15 tethered to its receptor alpha. In summary we have engineered persistence enhanced, allogeneic TRuC-T cells that maintain the signaling properties of the TCR complex with improved efficacy compared to donor-matched autologous TRuC-T cells.
|